Results 71 to 80 of about 49,935 (237)

Age‐Associated B Cells Contribute to Inflammation Via Antibody‐Independent Mechanisms in Takayasu Arteritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Although Takayasu arteritis (TAK) is not a prototypical autoantibody‐mediated disease, accumulating evidence suggests that B cells are involved. This study aimed to investigate the pathway of B cell activation and its contributions to TAK pathogenesis. Methods Histologic analysis of paravascular lymph nodes and affected arteries was conducted
Chenglong Fang   +10 more
wiley   +1 more source

Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis

open access: yes, 2018
Aim To examine the effects of tofacitinib, an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA), on composite endpoints in patients with PsA. Method In two Phase (P)3 studies, patients had active PsA and inadequate response (IR)
Hsu, M-A   +10 more
core   +1 more source

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

open access: yesArthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson   +127 more
wiley   +1 more source

Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation

open access: yesArthritis Research & Therapy, 2021
Background Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Heike C. Hawerkamp   +6 more
doaj   +1 more source

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic   +7 more
wiley   +1 more source

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis

open access: yes, 2013
Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected ...
Cutolo M   +3 more
core   +1 more source

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych   +10 more
wiley   +1 more source

Early diagnosis of axial spondyloarthritis is associated with less long‐term spinal structural damage: a longitudinal analysis of the Swiss Clinical Quality Management in rheumatic diseases registry

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration ≤2 years of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between early and established axSpA patients treated with biologic/targeted synthetic disease‐modifying anti ...
Annik Steimer   +18 more
wiley   +1 more source

Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice

open access: yesArthritis Research & Therapy, 2019
Background Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a sometimes life-threatening complication in RA patients. SKG mice develop not only arthritis but also an ILD resembling RA-ILD.
Sho Sendo   +4 more
doaj   +1 more source

Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report

open access: yes, 2023
Nan Luo, Lingyuan Zhong, Nana Luo, Qiuyue Wang, Tianhao Li, Pingsheng Hao Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaCorrespondence: Pingsheng Hao; Tianhao Li, Department ...
Luo N, Hao P, Wang Q, Li T, Zhong L
core  

Home - About - Disclaimer - Privacy